🚀 VC round data is live in beta, check it out!
- Public Comps
- Moolec Science
Moolec Science Valuation Multiples
Discover revenue and EBITDA valuation multiples for Moolec Science and similar public comparables like Steakholder Foods, ABVC BioPharma, Above Food, Local Bounti and more.
Moolec Science Overview
About Moolec Science
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
Founded
2022
HQ

Employees
72
Website
Financials (FY)
EV
$243M
Moolec Science Financials
Moolec Science reported last fiscal year revenue of $334M and negative EBITDA of ($110M).
In the same fiscal year, Moolec Science generated $126M in gross profit, ($110M) in EBITDA losses, and had net loss of ($111M).
Moolec Science P&L
In the most recent fiscal year, Moolec Science reported revenue of $334M and EBITDA of ($110M).
Moolec Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $334M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $126M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 38% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($110M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (33%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($111M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (33%) | XXX | XXX | XXX |
| Net Debt | — | — | $246M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Moolec Science Stock Performance
Moolec Science has current market cap of $5M, and enterprise value of $243M.
Market Cap Evolution
Moolec Science's stock price is $7.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $243M | $5M | 0.0% | XXX | XXX | XXX | $-153.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMoolec Science Valuation Multiples
Moolec Science trades at 0.7x EV/Revenue multiple, and (2.2x) EV/EBITDA.
Moolec Science Financial Valuation Multiples
As of April 21, 2026, Moolec Science has market cap of $5M and EV of $243M.
Equity research analysts estimate Moolec Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Moolec Science has a P/E ratio of (0.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5M | XXX | $5M | XXX | XXX | XXX |
| EV (current) | $243M | XXX | $243M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (69.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.9x | XXX | XXX | XXX |
| P/E | — | XXX | (0.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (22.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Moolec Science Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Moolec Science Margins & Growth Rates
Moolec Science's revenue in the last fiscal year grew by 97%.
Moolec Science's revenue per employee in the last FY averaged $4.6M, while opex per employee averaged $1.8M for the same period.
Moolec Science Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 97% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (33%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $4.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Moolec Science Public Comps
See public comps and valuation multiples for other Plant-Based Food comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Moolec Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Steakholder Foods | XXX | XXX | XXX | XXX | XXX | XXX |
| ABVC BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Above Food | XXX | XXX | XXX | XXX | XXX | XXX |
| Local Bounti | XXX | XXX | XXX | XXX | XXX | XXX |
| Jyong Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Moolec Science M&A Activity
Moolec Science acquired XXX companies to date.
Last acquisition by Moolec Science was on XXXXXXXX, XXXXX. Moolec Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Moolec Science
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMoolec Science Investment Activity
Moolec Science invested in XXX companies to date.
Moolec Science made its latest investment on XXXXXXXX, XXXXX. Moolec Science invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Moolec Science
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Moolec Science
| When was Moolec Science founded? | Moolec Science was founded in 2022. |
| Where is Moolec Science headquartered? | Moolec Science is headquartered in Argentina. |
| How many employees does Moolec Science have? | As of today, Moolec Science has over 72 employees. |
| Who is the CEO of Moolec Science? | Moolec Science's CEO is Alejandro Antalich. |
| Is Moolec Science publicly listed? | Yes, Moolec Science is a public company listed on Nasdaq. |
| What is the stock symbol of Moolec Science? | Moolec Science trades under MLECW ticker. |
| When did Moolec Science go public? | Moolec Science went public in 2023. |
| Who are competitors of Moolec Science? | Moolec Science main competitors are Steakholder Foods, ABVC BioPharma, Above Food, Local Bounti. |
| What is the current market cap of Moolec Science? | Moolec Science's current market cap is $5M. |
| What is the current revenue of Moolec Science? | Moolec Science's last fiscal year revenue is $334M. |
| What is the current EV/Revenue multiple of Moolec Science? | Current revenue multiple of Moolec Science is 0.7x. |
| Is Moolec Science profitable? | No, Moolec Science is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.